Albany, NY -- (SBWIRE) -- 07/03/2019 -- Progressive Supranuclear Palsy Market Insights, Epidemiology and Market Forecast-2028
1. Approximately 20,000 people are affected with Progressive Supranuclear Palsy in the United States
2. Progressive Supranuclear Palsy prevalence is approximately 5 per 100,000 in the United States
3. The age-adjusted prevalence rate of PSP in another study from the UK was estimated at 6.4 per 100,000
DelveInsight launched a new report on Progressive Supranuclear Palsy Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Progressive Supranuclear Palsy market report covers a descriptive overview and comprehensive insight of the Progressive Supranuclear Palsy epidemiology and Progressive Supranuclear Palsy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Progressive Supranuclear Palsy market report provides insights on the current and emerging therapies.
3. Progressive Supranuclear Palsy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Progressive Supranuclear Palsy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Progressive Supranuclear Palsy market.
Request for sample pages
"The age? and sex?adjusted Progressive Supranuclear Palsy prevalence per 100,000 people in Japan was 17.26 (male = 18.14; female = 16.63)"
Progressive Supranuclear Palsy treatment is symptomatic and supportive; however, the symptoms usually do not respond to medications. In some individuals, the slowness, stiffness, and balance problems of Progressive Supranuclear Palsy may respond to some degree to antiparkinsonian agents such as levodopa, but the effect is usually minimal and short-lasting. Zolpidem, a GABA agonist, may improve motor function, dysarthria and ocular abnormalities according to anecdotal evidence from case reports. Memantine may provide symptomatic benefit in patients with PNFA. However, excessive eye closing can be treated with Botulinum injections, as well as, some antidepressant drugs may also provide benefit beyond treating depression, such as pain relief and decreasing drooling.
However, with an increasing Progressive Supranuclear Palsy prevalent population, and high unmet need, various companies are developing Progressive Supranuclear Palsy therapies for the patients. In the coming years, Progressive Supranuclear Palsy market outlook can see a drastic change.
Key players mentioned below are developing Progressive Supranuclear Palsy therapies
1. AbbVie
2. Asceneuron SA
3. Biogen
4. Aprinoia therapeutics
5. Alzprotect
The expected launch of Progressive Supranuclear Palsy emerging therapies such as
1. ABBV-8E12
2. BIIB092
3. APN 1607
4. ASN120290
Table of contents
1. Key Insights
2. Progressive Supranuclear Palsy Epidemiology Overview at a Glance
3. Progressive Supranuclear Palsy Disease Background and Overview
4. Progressive Supranuclear Palsy Epidemiology and Patient Population
5. Progressive Supranuclear Palsy Total Prevalent Patient Population 7MM
6. Progressive Supranuclear Palsy Country Wise-Epidemiology
6.1. United States
6.2. EU5 Countries
6.2.1.Germany
6.2.2.France
6.2.3.Italy
6.2.4.Spain
6.2.5.United Kingdom
6.3. Japan
7. Progressive Supranuclear Palsy Treatment Algorithm
8. Progressive Supranuclear Palsy Unmet needs
9. Progressive Supranuclear Palsy Emerging drugs
9.1. Key Cross Competition
9.2. ABBV-8E12: AbbVie
9.3. BIIB092: Biogen
9.4. APN 1607: Aprinoia therapeutics
9.5. ASN120290: Asceneuron SA
10. Progressive Supranuclear Palsy 7 Major Market Analysis
11. Progressive Supranuclear Palsy Market Size in 7MM
12. Market Outlook by Country
12.1. The United States: Market Outlook
12.2. EU-5 Countries: Market Outlook
12.2.1. Germany
12.2.2. France
12.2.3. United Kingdom
12.2.4. Spain
12.2.5. Italy
12.3. Japan: Market Outlook
13. Market Drivers
14. Market Barriers
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight